Internal Medicine, Hematology & Oncology · Tulsa, OK
NPI
1447606348
Since 2016
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
12697 E 51st St
Tulsa, OK, 74146
Phone (918) 505-5320
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.3M
171,529 services
Medicare patients, 2024
821
Average age 74
Drug cost, 2024
$7.7M
2,026 prescriptions
Company payments, 2025
$107K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Caleb J Scheckel was code Q9967 (low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml), 13,320 times for 130 patients. In total Caleb J Scheckel billed 171,529 services in 232 codes, and Medicare paid $3.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-14.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 13,320 | 130 | $0.10 | $1,339 |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 11,250 | 15 | $0.87 | $9,813 |
| J9299 Injection, nivolumab, 1 mg | Office | 10,620 | 19 | $24.72 | $263K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 9,000 | 31 | $44.96 | $405K |
| J9267 Injection, paclitaxel, 1 mg | Office | 7,675 | 33 | $0.08 | $619 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 7,560 | 24 | $39.43 | $298K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 6,900 | 57 | $4.40 | $30K |
| J0185 Injection, aprepitant, 1 mg | Office | 5,330 | 33 | $1.33 | $7,065 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 5,300 | 11 | $0.05 | $283 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,300 | 17 | $0.11 | $373 |
| J0897 Injection, denosumab, 1 mg | Office | 2,700 | 24 | $20.73 | $56K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,619 | 160 | $0.09 | $235 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2,190 | 12 | $2.32 | $5,082 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2,120 | 26 | $33.28 | $71K |
| 85025 Blood Count | Office | 2,111 | 265 | $7.59 | $16K |
By year: 2022 $25K for 669 services; 2023 $2.6M for 153,106 services; 2024 $3.3M for 171,529 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,111 | 265 | $7.59 | $16K |
| 83615 Clinical Chemistry | 1,904 | 248 | $5.90 | $11K |
| 83735 Clinical Chemistry | 1,903 | 248 | $6.54 | $12K |
| 84550 Clinical Chemistry | 1,902 | 248 | $4.41 | $8,397 |
| 84100 Clinical Chemistry | 1,902 | 248 | $4.63 | $8,810 |
| 80053 Clinical Chemistry | 1,897 | 249 | $10.31 | $20K |
| 36415 Venipuncture Blood Collection | 1,541 | 251 | $8.64 | $13K |
| 88185 Surgical Pathology Examination | 1,344 | 58 | $16.34 | $22K |
| 85055 Blood Count | 455 | 92 | $34.88 | $16K |
| 82784 Immunoassay | 189 | 52 | $9.11 | $1,722 |
Medicare prescription drug claims, 2024
In 2024, the drug Caleb J Scheckel prescribed most often to Medicare patients was Acyclovir, with 218 prescriptions and refills. In total Caleb J Scheckel wrote 2,026 Medicare prescriptions that cost $7.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 218 | 273 | 45 | $3,217 |
| Revlimid Lenalidomide | 120 | 120 | 18 | $2.3M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 92 | 116 | 25 | $484 |
| Venclexta Venetoclax | 90 | 90 | 16 | $478K |
| Ondansetron Odt Ondansetron | 83 | 83 | 36 | $1,068 |
| Levofloxacin Generic | 72 | 74 | 32 | $1,025 |
| Dexamethasone Generic | 68 | 105 | 24 | $1,112 |
| Valacyclovir Valacyclovir Hcl | 66 | 81 | Under 11 | $2,141 |
| Prednisone Generic | 62 | 75 | 29 | $237 |
| Brukinsa Zanubrutinib | 59 | 59 | Under 11 | $717K |
| Eliquis Apixaban | 54 | 56 | 15 | $31K |
| Hydroxyurea Generic | 52 | 86 | 13 | $1,260 |
| Oxycodone Hcl Generic | 42 | 42 | 16 | $529 |
| Ondansetron Hcl Generic | 36 | 36 | 13 | $297 |
| Potassium Chloride Generic | 34 | 37 | 17 | $548 |
Brand drugs: 579 claims; generic drugs: 1,447 claims; opioid claims: 124.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Caleb J Scheckel $107K ($107K in general payments such as food, travel and fees) from 21 companies. The largest payer was Pfizer Inc. with $33K.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 21 | $33K |
| BeOne Medicines USA, Inc. ONC | 17 | $30K |
| AstraZeneca Pharmaceuticals LP AZN | 20 | $30K |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $12K |
| BeiGene USA, Inc. ONC | 1 | $1,875 |
| Janssen Biotech, Inc. JNJ | 3 | $173 |
| Adaptive Biotechnologies Corporation ADPT | 1 | $139 |
| Adc Therapeutics America, Inc. | 1 | $108 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $36.97 |
| Aveo Pharmaceuticals, Inc. | 1 | $35.79 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.